Donald L. Morton, M.D ., John F. Thompson, M.D., Alistair J. Cochran, M.D., Nicola Mozzillo, M.D., Omgo E. Nieweg, M.D., Ph.D., Daniel F. Roses, M.D., Harold J. Hoekstra, M.D., Ph.D., Constantine P. Karakousis, M.D., Ph.D., Christopher A. Puleo, P.A.-C., Brendon J. Coventry, B.M., B.S., Ph.D., Mohammed Kashani-Sabet, M.D., B. Tag Smithers, M.B., B.S., Eberhard Paul, M.D., William G. Kraybill, M.D., J. Gregory McKinnon, M.D., He-Jing Wang, M.D., Robert Elashoff, Ph.D., and Tag B. Faries, M.D. For the MSLT Group: Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma Regional node management in melanoma has remained controversial since Snow1 recommended elective total lymphadenectomy for all patients with melanoma, of whether there was clinical evidence of regional nodal metastases regardless.

Randomization was stratified regarding to medical center and self-reported race . Genotyping to get CYP2C9 and VKORC1 at each medical center was performed with the use of one of two FDA-approved platforms, the GenMark Dx eSensor XT-8 or the AutoGenomics INFINITI Analyzer. Per protocol, genotyping was performed in every patients after blood-sample collection to maintain blinding to the procedure assignment immediately. Genotyping was repeated at the central laboratory by using either pyrosequencing or real-time polymerase-chain-reaction assay to measure the accuracy at clinical centers. Study Intervention and Follow-up The scholarly study intervention period was the first 5 times of warfarin therapy. During this time period, the prespecified algorithms had been used to determine the warfarin dose.